Resource Summary Report

Generated by ASWG on Aug 9, 2026

CD8+ T Cell Isolation Kit, human

RRID:AB_3073903
Type: Antibody

Proper Citation

(Miltenyi Biotec Cat# 130-096-495, RRID:AB_3073903)

Antibody Information

URL: http://antibodyregistry.org/AB_3073903

Proper Citation: (Miltenyi Biotec Cat# 130-096-495, RRID:AB_3073903)

Target Antigen: CD4, CD15, CD16, CD19, CD34, CD36, CD56, CD123, TCR?/?, CD235a (Glycophorin A)

Clonality: cocktail

Antibody Name: CD8+ T Cell Isolation Kit, human

Description: This cocktail targets CD4, CD15, CD16, CD19, CD34, CD36, CD56, CD123, TCR?/?, CD235a (Glycophorin A)

Target Organism: human

Antibody ID: AB_3073903

Vendor: Miltenyi Biotec

Catalog Number: 130-096-495

Record Creation Time: 20260218T234155+0000

Record Last Update: 20260226T000321+0000

Ratings and Alerts

No rating or validation information has been found for CD8+ T Cell Isolation Kit, human.

No alerts have been found for CD8+ T Cell Isolation Kit, human.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at ASWG .

Weber PAA, et al. (2026) Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control. Cancer research communications, 6(7), 1619.

Kim Y, et al. (2024) Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell host & microbe, 32(8), 1380.